Shortcuts to body


합성 유전자 서열
Synthetic construct for Interleukin 11 receptor alpha using Human scFv antibody, sequence

  • Accession
    KSYN010000000004
  • Submission date
    2025-09-09

Project Detail
BioProject detail - BioProject ID, projectTitle, projectDescription, keywords, nameOfSubmitter
BioProject
KAP241593
프로젝트의 영문 제목
Development of novel IL-11 neutralizing antibody for liver fibrosis
프로젝트의 영문 설명
Development of novel IL-11 neutralizing antibody
등록자의 영문 이름
YANG WONJUN

DataSet
메타데이터 입력
Name of submitter's organization
Korea Research Institute of Bioscience and Biotechnology(KRIBB)
Department of submitter
Korea Research Institute of Bioscience and Biotechnology(KRIBB)
Country of submitter
South Korea
Street address
125 Gwahak-ro
City
Yuseong-gu
State / Province / Region
Daejeon
Zip Code (Postal Code)
34141
Contact person information
Name
Email
wonjun@kribb.re.kr
Phone
Publication status
Unpublished
Publication
PubMed ID of publication
DOI of publication
Reference Title
Authors
Journal Title
Journal Year
Journal Volume
Journal Issue
Journal Pages
Publication
Reference title
Confirm update of existing submission
No
Existing KNA Accession ID
Sequence Authors
Sequence authors full name
Wonjun Yang
Sequence authors initials
Yang,W.
Sample processing protocol
Data processing protocol
Supplementary information
Release Protocol?
No
Topology
Feature Information
Feature Description
Strand
Status
Partial
Nucleotide Interval Spans
Interval
Start
Stop
Sequence source (Backbone)
Human scFv antibody
Sequence source Accession
NCBI Accession
KNA Accession ID
Target
Interleukin 11 receptor alpha
Name
P3C35
Purpose
anti-IL-11 receptor alpha scFv antibody
Description
This scFv antibody binds to human/mouse IL-11 recpetor alpha
Annotation file format
None
Total length
723
Total contigs
1
Scaffolds or chromosomes Total length
Scaffolds or chromosomes Total contigs

File
file 목록
File Name Size Type Published Download
Synthetic construct for Interleukin 11 receptor alpha using Human scFv antibody, sequence.fasta 757 757 fasta 2026-05-31
TOP 위로가기